Seeking Alpha

Immunomedics (IMMU -2.2%) finishes the day lower, despite reporting favorable results from the...

Immunomedics (IMMU -2.2%) finishes the day lower, despite reporting favorable results from the study of its proprietary humanized antibody, clivatuzumab tetraxetan, as a treatment for patients with advanced, inoperable, pancreatic cancer.
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Tools
Find the right ETFs for your portfolio:
Seeking Alpha's new ETF Hub
ETF Investment Guide:
Table of Contents | One Page Summary
Read about different ETF Asset Classes:
ETF Selector

Next headline on your portfolio:

|